Netherland-based injectable drug delivery products producer InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan (AGN), to develop new medicines for ophthalmic diseases.
Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets.
Specialty pharmaceutical company Supernus Pharmaceuticals is set to launch once-daily extended release formulation of topiramate, Trokendi XR, to treat epilepsy following the final FDA approval.
Amedra Pharmaceuticals has re-launched a single-dose epinephrine auto-injector Adrenaclick for people with increased risk of anaphylaxis in both 0.15mg and 0.30mg strengths.
Adimab and Innovent have collaborated to discover, develop and commercialise an antibody-based therapeutic, using Adimab antibody discovery and optimization platform, against a selected specific target.
Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US.
Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity.